[The effects of lupus anticoagulant on pulmonary thromboembolism]

Zhonghua Jie He He Hu Xi Za Zhi. 2004 Nov;27(11):740-2.
[Article in Chinese]

Abstract

Objective: To evaluate the effects of lupus anticoagulant (LA) on pulmonary thromboembolism (PTE).

Methods: Thirty-eight patients with PTE (17 massive and 21 submassive) and 30 healthy adults were studied. Russell's viper venom time (RVVT) was used to examine the ratio of LA (LAR), and a colorimetric method was used to detect the activity of plasma protein C (PC:A) and radioimmunoassay (RIA) was employed to measure the level of plasma thromboxane B(2) (TXB(2)) and 6-keto-prostaglandin F1alpha (6-keto-PGF1alpha).

Results: Compared with the normal group, LAR, TXB(2) and TXB(2)/6-keto-PGF1alpha showed significant increase in the massive PTE and the submassive PTE groups (P < 0.01), and the levels were higher in the massive group than in the submassive group (P < 0.01). Both groups showed significant decrease in PC:A and 6-keto-PGF1alpha compared with the normal group (P < 0.01).

Conclusions: LA can increase TXB(2)/6-keto-PGF1alpha and decrease PC:A in patients with PTE. It is suggested that there may be an association between the increase of LAR and the presence of PTE.

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 6-Ketoprostaglandin F1 alpha / blood*
  • Adult
  • C-Reactive Protein / analysis*
  • Female
  • Humans
  • Lupus Coagulation Inhibitor / blood*
  • Lupus Coagulation Inhibitor / physiology
  • Male
  • Middle Aged
  • Prostaglandins / blood
  • Pulmonary Embolism / blood*
  • Pulmonary Embolism / etiology
  • Pulmonary Embolism / pathology
  • Radioimmunoassay
  • Thromboembolism / prevention & control
  • Thromboxane B2 / blood*

Substances

  • Lupus Coagulation Inhibitor
  • Prostaglandins
  • Thromboxane B2
  • 6-Ketoprostaglandin F1 alpha
  • C-Reactive Protein